Neurotrophic Keratopathy

Sponsor – OYSTER POINT (Recruitment/Not yet Open)

Study: Olympia OPP-102
A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (varenicline) Nasal Spray in Subjects with Neurotrophic Keratopathy (the Olympia Study)
https://clinicaltrials.gov/ct2/show/NCT04469595?term=NEW+DAY&draw=2&rank=1